| Ref ID |
Mobility |
Bone Pain |
Grip Strength |
Bone Meta/Biomarkers |
Linear growth |
| Henderson 2002 |
N/A |
N/A |
N/A |
NTx was reduced in treatment group and remained low for 6 months after last dose
No change in osteocalcin, bone‐specific alkaline phosphatase |
N/A |
| El‐Husseini 2004 |
N/A |
N/A |
N/A |
No statistically significant differences, pre‐ and post‐treatment |
N/A |
| Rudge 2005 |
N/A |
N/A |
N/A |
N/A |
Mean height velocity was similar in the treatment group (4.2 cm/year, Z‐score ‐1.4) and in the placebo group (4.5 cm/year, Z‐score ‐1.3) |
| Bianchi 2000 |
N/A |
No bone pain reported in treated group |
N/A |
uNTx decreased by 27 +/‐ 16.5% in treatment group (not measured in control group) |
In pre‐pubertal children (Tanner stages 1 and 2) yearly increase in height was 2.9 +/‐ 1.2 cm during the study, compared with 2.8+/‐ 1.1 cm in the year preceding the study (considered satisfactory by investigators) |
| Acott 2005 |
N/A |
All patients had a resolution of their bone pain after 48 hours of treatment |
N/A |
No statistically significant differences, pre‐ and post‐treatment |
Annual growth rates of the treated and control groups were not different |
| Lepore 1991 |
N/A |
N/A |
N/A |
N/A |
N/A |
| Golden 2005 |
N/A |
N/A |
N/A |
N/A |
N/A |
| Klein 2005 |
N/A |
N/A |
N/A |
No statistically significant differences, pre‐ and post‐treatment |
N/A |
| Kim 2006 |
N/A |
N/A |
N/A |
No statistically significant changes in serum calcium, BUN, and creatinine level.
Serum phosphate level decreased in the control (P<0.05) and treatment groups (P<0.05). The ALP level also decreased in the control (P<0.001) and treatment (P<0.001) groups.
Serum PTH level increased in the control (P<0.001) and treatment (P<0.001) groups. Serum osteocalcin levels decreased in control (P<0.001) and treatment (P<0.001) groups. Serum osteocalcin levels decreased in control (P<0.001) and treatment (P<0.001) groups. Urine pyridinoline levels decreased in control (P<0.001) and treatment (P<0.001) groups. |
N/A |
